The Medical Products Agency (MPA) in Sweden has authorised Herantis Pharma PLC and Renishaw PLC’s clinical study for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) in Parkinson’s patients.
The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm. Two other university hospitals are scheduled to join the study later. The clinical study intends to recruit a total of 18 patients with Parkinson’s disease.
Paul Skinner, general manager for Renishaw’s neurological products division, said: “This is an important step forward in the use of the Renishaw drug delivery system, and in gathering clinical data for the delivery of therapeutics across the blood-brain barrier.”
Parkinson’s is a neurodegenerative disease, caused by the breakdown of dopamine-producing neurons in the brain. Symptoms include involuntary shaking, stiffness of muscles and slowing down of movement.
Whilst these symptoms can initially be managed with medication, there is currently no treatment available that effectively prevents disease progression, or that treats the motor and non-motor symptoms together.
CDNF aims to relieve the symptoms of Parkinson’s by protecting dopaminergic neurons and restoring their functionality. However, due to the size of the molecule, it will not cross the blood-brain barrier and must therefore be delivered directly into the brain.
The clinical study received funding under the Horizon 2020 research and innovation programme.